Eric Hatterer

Title: Eric Hatterer: Innovator in Targeted Cancer Therapies

Introduction

Eric Hatterer is a notable inventor based in Valleiry, France. He has made significant contributions to the field of cancer treatment through his innovative research and development of bispecific antibodies. His work focuses on targeted therapies that aim to improve the efficacy of treatments for GPC3 positive malignancies.

Latest Patents

Eric Hatterer holds a patent for "Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells." This invention relates to GPC3×CD3 bispecific antibodies, GPC3×CD28 bispecific antibodies, and the combination of these two agonistic and fully human KA-bodies. The antibodies target GPC3 without competing for binding, providing a novel approach for treating GPC3 positive malignancies. He has 1 patent to his name.

Career Highlights

Eric Hatterer is associated with Lamkap Bio Gamma Ag, where he continues to advance his research in the field of immunotherapy. His work has the potential to significantly impact the treatment landscape for patients with specific types of cancer.

Collaborations

Eric collaborates with talented professionals in his field, including Anja Seckinger and Dirk Hose. Their combined expertise contributes to the innovative research and development efforts at Lamkap Bio Gamma Ag.

Conclusion

Eric Hatterer is a pioneering inventor whose work in bispecific antibodies represents a promising advancement in targeted cancer therapies. His contributions are vital in the ongoing fight against GPC3 positive malignancies.